公开(公告)号：WO2021067644A1

公开(公告)日：2021-04-08

申请号：PCT/US2020/053870

申请日：2020-10-01

申请人： SILVERBACK THERAPEUTICS, INC.

发明人： ODEGARD, Valerie ,  BAUM, Peter R. ,  THOMPSON, Peter A.

IPC分类号： A61K47/68 ,  A61K45/06 ,  A61P35/00

摘要： Combination therapies using a conjugate comprising a TLR agonist and an antibody that binds a tumor associated antigen or liver cell antigen, and a second therapeutic agent, such as an immune checkpoint inhibitor, are provided for treating cancer or viral infections. Combination therapies using a conjugate comprising a TLR agonist and an antibody that binds HER2, and a second therapeutic agent are also provided for treating cancer.

公开(公告)号：WO2022006327A1

公开(公告)日：2022-01-06

申请号：PCT/US2021/039974

申请日：2021-06-30

申请人： SILVERBACK THERAPEUTICS, INC.

发明人： BAUM, Peter R. ,  DUBOSE, Robert ,  ODEGARD, Valerie ,  TAN, Philip ,  THOMPSON, Peter A. ,  SMITH, Sean W. ,  STEVENS, Brenda

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61P1/16 ,  A61K47/6803 ,  A61K47/6849 ,  C07K16/2851 ,  C07K2317/24 ,  C07K2317/565

摘要： The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.

公开(公告)号：WO2022006340A1

公开(公告)日：2022-01-06

申请号：PCT/US2021/039995

申请日：2021-06-30

申请人： SILVERBACK THERAPEUTICS, INC.

发明人： SMITH, Sean W. ,  BAUM, Peter R. ,  DUBOSE, Robert ,  ODEGARD, Valerie ,  TAN, Philip ,  THOMPSON, Peter A. ,  STEVENS, Brenda ,  HUNT, Kevin W.

IPC分类号： C07D401/14 ,  C07K5/062 ,  C07K5/065 ,  C07K5/093 ,  C07K5/113 ,  C07K7/06 ,  A61K31/498 ,  A61K47/68 ,  A61P35/00 ,  A61K47/6803 ,  C07K5/06052 ,  C07K5/06078 ,  C07K5/0819 ,  C07K5/1021

摘要： ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.The disclosed compoundsand conjugates are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5.

公开(公告)号：WO2021072203A1

公开(公告)日：2021-04-15

申请号：PCT/US2020/055000

申请日：2020-10-09

申请人： SILVERBACK THERAPEUTICS, INC.

发明人： BAUM, Peter R. ,  DUBOSE, Robert ,  ODEGARD, Valerie ,  TAN, Philip ,  THOMPSON, Peter A. ,  SMITH, Sean W. ,  STEVENS, Brenda

IPC分类号： A61K47/68 ,  A61P1/16

摘要： Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.